Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719459 · ClinicalTrials.gov registry record · Phase 1
Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer
A Phase 1 study, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00719459 is a Phase 1 study that has completed, run by Hospira, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT00719459, a Phase 1 study, has completed, sponsored by Hospira, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the bioequivalence of the test product Hospira Iron Sucrose 20 mg/mL (Hospira, Inc.) to the reference product Venofer® 20 mg/mL following intravenous administration to healthy subjects.
Interventions
- DRUG Iron Sucrose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-07-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00719459
The ClinicalTrials.gov registry entry for NCT00719459 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Iron Sucrose is the first listed.
NCT00719459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00719459 about?
NCT00719459 is a clinical study titled "Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer". The primary objective of this study is to assess the bioequivalence of the test product Hospira Iron Sucrose 20 mg/mL (Hospira, Inc.) to the reference product Venofer® 20 mg/mL following intravenous administration to healthy subjects.
What is the current status of trial NCT00719459?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2008-06. Estimated completion is 2008-07-13.
What interventions are being tested in trial NCT00719459?
The interventions under investigation include: Iron Sucrose (DRUG).
Who is sponsoring clinical trial NCT00719459?
This trial is sponsored by Hospira, now a wholly owned subsidiary of Pfizer, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.